Shi Hongshuo, Dong Chengda, Wang Min, Liu Ruxue, Wang Yao, Kan Zunqi, Wang Lei, Si Guomin
Shandong University of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Jinan, China.
Shandong University of Traditional Chinese Medicine, Experimental Center, Jinan, China.
Ann Transl Med. 2021 Jan;9(2):164. doi: 10.21037/atm-20-8165.
Vascular dementia (VaD) is a degenerative cerebrovascular disease that leads to progressive decline of patients' cognitive ability and memory. Yizhi Tongmai (YZTM) decoction is an empirical prescription first formulated by Professor Guomin Si. Our previous experiments proved the effectiveness of this prescription in the treatment of VaD. In this study, we aimed to use network pharmacology and molecular docking technology to systematically explain the potential anti-VaD mechanism of YZTM.
We identified the core compounds of YZTM and their potential targets through the TCMSP, BATMAN, and SwissTargetPrediction databases. Then, we identified the molecular targets of YZTM in VaD using the Online Mendelian Inheritance in Man and GeneCards databases. The common targets of YZTM and VaD were screened out, and then the pathways of these target genes were analyzed using the Database for Annotation, Visualization and Integrated Discovery v6.8. Molecular docking was used to verify the relationship between the core compounds and proteins.
Through network pharmacology analysis, we discovered that the 5 core compounds in YZTM exert an anti-VaD effect. The potential mechanism of YZTM anti-VaD may be through inhibiting the NLRP3 inflammasome, TNF signaling pathway, and toll-like receptor signaling pathways. Subsequently, key compounds were docked with related proteins in the NLRP3 inflammasome (NLRP3, ASC, caspase-1, interleukin-18, and interleukin-1 β) using molecular docking technology. The compounds were found to spontaneously bind to the proteins.
YZTM may exert an anti-VaD effect through inhibition of the NLRP3 inflammasome. In addition, TNF signaling pathway and toll-like receptor signaling pathway may also be its underlying mechanism. The application of network pharmacology and molecular docking technology may provide a novel method for research of Chinese herbal medicine. YZTM may also provide a complementary treatment option for patients with VaD.
血管性痴呆(VaD)是一种退行性脑血管疾病,会导致患者认知能力和记忆力逐渐下降。益智通脉(YZTM)汤是司国民教授首次配制的经验方。我们之前的实验证明了该方在治疗VaD方面的有效性。在本研究中,我们旨在运用网络药理学和分子对接技术系统地阐释YZTM抗VaD的潜在机制。
我们通过中药系统药理学数据库与分析平台(TCMSP)、中药系统生物学与药物靶点数据库(BATMAN)和瑞士药物靶点预测数据库确定YZTM的核心化合物及其潜在靶点。然后,我们利用人类孟德尔遗传在线数据库(Online Mendelian Inheritance in Man)和基因卡片数据库(GeneCards)确定YZTM在VaD中的分子靶点。筛选出YZTM和VaD的共同靶点,然后使用注释、可视化与集成发现数据库(Database for Annotation, Visualization and Integrated Discovery v6.8)分析这些靶基因的通路。运用分子对接技术验证核心化合物与蛋白质之间的关系。
通过网络药理学分析,我们发现YZTM中的5种核心化合物具有抗VaD作用。YZTM抗VaD的潜在机制可能是通过抑制NLRP3炎性小体、肿瘤坏死因子(TNF)信号通路和Toll样受体信号通路。随后,利用分子对接技术将关键化合物与NLRP3炎性小体中的相关蛋白(NLRP3、凋亡相关斑点样蛋白(ASC)、半胱天冬酶-1、白细胞介素-18和白细胞介素-1β)进行对接。发现这些化合物能自发地与蛋白质结合。
YZTM可能通过抑制NLRP3炎性小体发挥抗VaD作用。此外,TNF信号通路和Toll样受体信号通路也可能是其潜在机制。网络药理学和分子对接技术的应用可能为中药研究提供一种新方法。YZTM也可能为VaD患者提供一种辅助治疗选择。